Augustin Albert J, Offermann Indre
Eye Clinic, Department of Ophthalmology, Moltkestrasse 90, 76133 Karlsruhe, Germany.
Expert Opin Emerg Drugs. 2006 Nov;11(4):725-40. doi: 10.1517/14728214.11.4.725.
Age-related macular degeneration (AMD) is a leading cause of blindness that until recently had no recognised drug treatment. In wet AMD, choroidal neovascularisation (CNV) causes a profound loss of central vision. CNV is a complex process in which tissue ischaemia and/or inflammation is thought to trigger production of angiogenic signal molecules. The release of VEGF appears to be particularly important. Verteporfin photodynamic therapy was the first drug therapy to be licensed for the treatment of some types of wet AMD. Other treatments directly targeting VEGF or other aspects of angiogenesis, such as pegaptanib, ranibizumab and anecortave acetate, have either recently been licensed or are in the advanced stages of development. These and other promising treatment options such as combination strategies are reviewed.
年龄相关性黄斑变性（AMD）是导致失明的主要原因，直到最近都没有公认的药物治疗方法。在湿性AMD中，脉络膜新生血管形成（CNV）会导致严重的中心视力丧失。CNV是一个复杂的过程，其中组织缺血和/或炎症被认为会触发血管生成信号分子的产生。血管内皮生长因子（VEGF）的释放似乎尤为重要。维替泊芬光动力疗法是首个被批准用于治疗某些类型湿性AMD的药物疗法。其他直接靶向VEGF或血管生成其他方面的治疗方法，如培加尼布、雷珠单抗和醋酸阿奈可他韦，要么最近已获得批准，要么正处于研发的后期阶段。本文对这些以及其他有前景的治疗选择（如联合策略）进行了综述。
